Paul Mathew, MD
Neurology · Cambridge, MANPI 1245495050
Payments from drug & device makers
Across 492 payments — averaging $461.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$89K
- AbbVie$72K
- Pfizer$28K
- Eli Lilly$7K
- Supernus Pharmaceuticals, Inc.$6K
- Axsome Therapeutics, Inc.$4K
- plus $22K from 22 others
Across 17 payments — averaging $1012.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$15K
- Novartis$2K
What the payments were for
- Consulting fees$81,61043%
- Speaking & faculty fees$73,67439%
- Travel & lodging$19,10010%
- Food & beverage$14,7188%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 128 | $88,671 |
| AbbVie(2 entities) | 163 | $71,917 |
| Pfizer | 35 | $27,544 |
| Eli Lilly | 18 | $6,512 |
| Supernus Pharmaceuticals, Inc. | 23 | $6,124 |
| Axsome Therapeutics, Inc. | 1 | $4,375 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $4,246 |
| Biohaven Pharmaceuticals, Inc. | 11 | $3,696 |
| Amgen | 5 | $3,588 |
| Tonix Medicines, Inc. | 16 | $3,430 |
| Upsher-smith Laboratories LLC | 14 | $3,148 |
| Lundbeck LLC | 23 | $1,325 |
| Teva Pharmaceuticals USA, Inc. | 14 | $705 |
| Novartis | 6 | $330 |
| Averitas Pharma Inc. | 3 | $315 |
| GRT US Holding, Inc. | 2 | $241 |
| Impel Pharmaceuticals Inc. | 3 | $214 |
| Promius Pharma LLC | 2 | $197 |
| Biosense Webster, Inc. | 1 | $171 |
| Harmony Biosciences LLC | 2 | $151 |
| Ipsen Biopharmaceuticals, Inc | 2 | $140 |
| Eisai Inc. | 1 | $57 |
| Tris Pharma Inc | 1 | $33 |
| Merz Pharmaceuticals, LLC | 1 | $29 |
| Vertex | 1 | $23 |
| SK Life Science, Inc. | 1 | $21 |
| Pernix Therapeutics Holdings, Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$16,211
- EMGALITY$12,950
- UBRELVY$12,522
- QULIPTA$10,936
- BOTOX$9,858
- ZAVZPRET$7,668
- TROKENDI XR$5,876
- TOSYMRA$4,895
- ZEMBRACE SYMTOUCH$4,533
- AIMOVIG$3,773
- VYEPTI$482
- Qutenza$432
- AJOVY$248
- QDOT MICRO Catheter$171
- Trudhesa$137
- Wakix$128
How this compares
$227,237 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 178 | $230,093 |
| UbrelvyUbrogepant | 138 | $210,120 |
| Nurtec OdtRimegepant Sulfate | 88 | $168,426 |
| Emgality PenGalcanezumab-Gnlm | 70 | $71,337 |
| Sumatriptan Succinate | 224 | $70,779 |
| Aimovig AutoinjectorErenumab-Aooe | 81 | $62,979 |
| Zembrace SymtouchSumatriptan Succinate | 17 | $37,745 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 40 | $35,092 |
| Emgality SyringeGalcanezumab-Gnlm | 23 | $20,786 |
| ReyvowLasmiditan Succinate | 18 | $18,376 |
| Eletriptan HbrEletriptan Hydrobromide | 39 | $5,710 |
| Pregabalin | 94 | $3,800 |
| Gabapentin | 232 | $2,721 |
| RizatriptanRizatriptan Benzoate | 122 | $2,101 |
| Zolmitriptan | 51 | $2,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $71,917 | $440,213316 claims |
| PfizerNurtec Odt | $27,544 | $168,42688 claims |
| Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate | $3,148 | $38,64292 claims |
| Lilly USA, LLCReyvow | $88,671 | $18,37618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.
Other neurology in Cambridge
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Donald MarksPlymouth$7.8M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.